When genomic medicine reveals misattributed genetic relationships – the debate about disclosure revisited by Wright, C et al.
 1 
TITLE  
When genomic medicine reveals misattributed genetic relationships – the debate about 
disclosure revisited 
 
SHORT RUNNING TITLE 
Managing misattributed parentage in family sequencing studies 
 
 
Wright C.F. PhD1, Parker M. PhD2, Lucassen A.M. FRCP DPhil3* 
 
1 Institute of Biomedical and Clinical Science, University of Exeter Medical School, RILD Level 4, Royal 
Devon & Exeter Hospital, Barrack Road, Exeter, EX2 5DW, UK 
 
2 The Wellcome Centre for Ethics and Humanities/ Ethox Centre, Nuffield Department of Population Health, 
University of Oxford, Old Road Campus, Oxford OX3 7LF, UK 
 
3 Clinical Ethics and Law, Faculty of Medicine, University of Southampton, Southampton, SO16 5YA, UK 
 
* Corresponding author: a.m.lucassen@soton.ac.uk; +44 (0)23 8120 4489		  
 
 
 
All authors contributed equally to this manuscript.  
 2 
ABSTRACT 
 
Purpose: Accidental discovery of misattributed parentage is an age-old problem in clinical 
medicine, but the ability to detect it routinely has increased recently as a result of high-
throughput DNA sequencing technologies coupled with family sequencing studies. Problems 
arise at the clinical-research boundary, where policies and consent forms guaranteeing 
nondisclosure may conflict with standard clinical care. Methods: To examine the challenges 
of managing misattributed parentage within hybrid translational research studies, we use a 
case study of a developmentally delayed child with a candidate variant found through a large-
scale trio genome sequencing study in which data from unrelated samples is routinely 
excluded. Results: We discuss whether genetic parentage should be explicitly confirmed 
during clinical validation, thus giving greater weight to the diagnosis according to ACMG 
variant interpretation guidelines, and what tensions this approach would create. Conclusion: 
We recommend that the possibility of finding and disclosing misattributed parentage should 
be addressed during the consent or pre-test counselling process, and that clinical relevance 
should determine whether or not to disclose results in the clinic. This proposition has 
implications for research governance, and implies that it may not always be possible to 
uphold nondisclosure commitments as investigations move from research to clinical care.  
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Introduction 
 
Rapid developments in high-throughput DNA sequencing technologies, resulting in increased 
speed and decreased cost of analysis, have been well documented. Many hundreds of new 
disease-causing or predisposing genes have been identified in the last decade, leading to a 
marked increase in the number of diseases where the molecular aetiology is known.1,2 Many 
diseases have heritable subtypes, making these developments relevant to all medical 
specialities.3 Increasingly, genetic approaches to diagnosis use a single assay, in which either 
all the genes in the genome (the exome) or the entire genome is sequenced at once. In order 
to improve the interpretation of genomic variation, a comparison with the genetic code in 
close relatives can help to distinguish pathogenic from unknown or background variation. 
One commonly used method in paediatrics is trio testing, where a child’s genome is 
compared with both of their parents. This approach raises important questions about 
responsibilities for communicating parental genome results and determining whether they are 
relevant to the clinical question at hand. Findings that are incidental, additional or secondary 
to the initial clinical question are to be expected and require careful thought and sensitive 
management.4 
 
One of the oldest and most gnarly incidental findings in genetics is that of misattributed 
parentage, where testing reveals either the father, the mother, or both parents to be genetically 
unrelated to their child, or not related as stated. The increased use of genome-wide trio 
sequencing, particularly in paediatrics,5,6 will definitively prove biological relationships in a 
way that previous targeted approaches did not. This can pose a dilemma for the professionals 
who handle genomic data from trios as to what to do with such information. Some large-scale 
family-based sequencing studies – such as the Deciphering Developmental Disorder (DDD) 
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Study7 and the 100,000 Genomes Project8 in the UK – have made explicit statements that 
they would never reveal information about misattributed parentage. But the hybrid nature of 
such studies, that lie at the interface between clinical practice and research, can lead to 
situations in which such promises clash with views about good clinical practice, e.g. where 
facts about familial relationships are directly relevant to clinical care. Coupled with the 
specific aim of such studies to deliver diagnostic results to individual families, routine 
confirmatory tests may definitively prove something that the clinical teams were not 
expecting, and then feel uncertain about if, when, and how to communicate.  
 
In this paper, we illustrate some of the practical and ethical issues that surround the discovery 
of misattributed parentage using the following case study: 
 
Baby Sally has suffered from numerous developmental problems since she was born, 
and her parents were referred for genetic testing to find out the cause of her disorder 
before deciding whether to have another child. A molecular diagnosis could improve 
the management of Sally’s condition, suggest a prognosis, and predict the probability 
that her parents will have another similarly affected child. Desperate for an answer 
after numerous investigations have proved uninformative, the family agreed to be 
enrolled into a research study that would sequence all their DNA and communicate 
any potential diagnoses. However, the result was ambiguous: a novel variant was 
found in a gene in which other rare variation is known to cause a severe, dominant 
developmental disorder similar to Sally’s. Unfortunately, the inheritance of this 
variant is unknown because the parents’ samples failed analysis. Since this particular 
variant has not previously been described, it is not certain whether it explains Sally’s 
signs and symptoms. The interpretation of such a finding is challenging, due to the 
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enormous amount of benign variation across the genome even within genes that can 
cause severe disease. However, since both parents are healthy, the variant is only 
likely to be relevant if it arose spontaneously (a de novo mutation) and is only present 
in Sally, rather than inherited from either parent. The clinical team therefore decides 
to test both parents in their diagnostic laboratory to determine inheritance.  
 
Research versus clinical testing 
 
Before we discuss the result of the test in this case and its implications, it is worth pausing to 
consider two questions that might arise in relation to the decision to perform confirmatory 
testing.  
 
First, why did the parental samples fail analysis? There are numerous technical reasons why 
DNA analysis may fail, including sample mix-ups, low DNA yields, contamination, or poor 
data quality.7 However, familial samples collected for research studies may also be failed if 
they are not genetically related to each other in the expected manner. In a research setting, 
because such samples generally do not help to answer the overall research question, it is 
scientifically and economically prudent to exclude unrelated individuals from a family 
sequencing study as soon as possible to save the cost of full analysis. For this reason, 
researchers may use an initial genetic screen for quality control to identify sample mix-ups 
and unrelated trios (i.e. a genotype-based family analysis),9 then declare any unrelated 
parental samples invalid or failed, but still analyse the child’s genome. This approach also 
provides a mechanism of information control in studies that have an explicit policy around 
nondisclosure of misattributed parentage. Because of the different possible reasons a sample 
may ‘fail’, this means that the downstream clinical team would not know whether the 
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parental sample was insufficient for analysis or was unrelated to the child unless this was 
explicitly declared to them.  
 
Second, how should the clinical team act on this research finding? One step undertaken 
before any research findings are communicated to families is to check they are correct in an 
accredited diagnostic laboratory. Given that Sally’s clinicians do not know the reason for the 
parental sample failure, and that a more informative diagnostic result is likely if all three 
members of the trio are tested, should they now request new samples and proceed to confirm 
biological parentage (and thus inheritance) as well as the presence or absence of the variant 
itself? This presents another important question: what information should they provide to the 
parents about what this testing strategy might reveal? Information about biological parentage 
would allow the clinical team to interpret the significance of the novel finding in their patient 
and accurately counsel the parents about their risk of having another affected child. 
Confirming whether the variant arose de novo or not may be the deciding factor in whether it 
is considered pathogenic, or indeed diagnostic, in Sally’s case.10 
 
A further layer of complexity is added by the fact that these questions arise at the interface 
between research and clinical care. Any resolution requires careful consideration of the 
relationship between these two activities, their different motivations, the extent to which they 
are in practice separable, and the implications for relevant duties of care and lines of 
responsibility. The question presented by this case and others like it is not only what should a 
clinical team discuss with their patient or patient’s family, when supplementary testing to 
interpret the clinical significance of a finding would also uncover other types of information, 
but also what should researchers reveal to clinicians and diagnostic laboratories. Knowing 
when parentage has been misattributed can be extremely useful for deciding which diagnostic 
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testing strategy to use. Do researchers have a responsibility to impart information they hold 
that might be clinically useful, even if they have declared in their consent materials that they 
would not reveal such information (in this case, misattributed parentage) to research 
participants? How should this particular research-clinical boundary be negotiated? Since 
discovery of misattributed parentage is unavoidable when performing family-based genetic 
studies – either through genotype-based quality control procedures or whole exome/genome 
sequencing of the trio – a judgement must be made as to how far the information should be 
propagated along the chain of individuals and institutions involved in the study and care of 
the patient.  
 
This example serves to illustrate the difficulty of promising nondisclosure in one setting 
(research), when in another (clinical care), determining biological parentage can be extremely 
useful for guiding management. Providing ambiguous information to the clinical team may 
simply lead them to request new samples and perform their own trio testing, given its 
potential diagnostic utility. What are they to say at this stage, given that the initial research 
promised no information about genetic parentage would be provided? This can be illustrated 
by returning to the case with which we began this paper. 
 
Disclosure options 
 
The clinical team decides to do a full diagnostic confirmation of the research result, 
and discovers that the variant is not present in either parent, but genetic paternity has 
been misattributed – Sally’s father is biologically unrelated to her.  
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In this case, the finding of misattributed paternity has implications for the certainty of the 
diagnosis because it means that it is now impossible (with the samples available) to 
determine whether the single dominant variant is de novo and likely to be pathogenic, or has 
been inherited from the biological father and is likely to be benign. The finding also has 
implications for any conversation with the parents about the likelihood of this disease 
occurring in any future child they might have – an issue that is central to cases such as 
Sally’s, but may not be relevant for everyone. This raises important questions for the clinical 
team: should they limit their discussion with the family to the likely diagnosis, emphasising 
that the chance of this happening in a future child of this couple is extremely low (since they 
know the variant was not inherited from either of Sally’s stated parents)? Should they also 
raise the possibility that the true diagnosis has been missed, thus making it impossible to 
accurately counsel the parents about recurrence risk? Or should they discuss the question of 
genetic relatedness, and perhaps even attempt to obtain a DNA sample from the ‘genetic 
father’ to confirm the diagnosis? If they take the former approach, what should they do about 
recording the information and the test results in Sally’s clinical records, and how should they 
respond if asked a direct question about genetic paternity (or about reproductive implications) 
during the consultation? What responsibilities do the clinicians have to be open and honest 
about all of their findings and interpretations with the parents who have come to them 
seeking information about Sally’s condition, its cause, and the reproductive implications?  
 
One possibility would be to seek to discuss the result with Sally’s mother alone as she is 
likely to be aware of the possibility of misattributed paternity. However, were this course of 
action to be chosen, the information may not be shared with Sally’s father leaving him to 
believe, wrongly, that any future pregnancies would potentially be at significant risk when in 
fact the risk is negligible. This would mean knowingly allowing a patient to leave the clinic 
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with a false belief about his reproductive risk, thereby undermining the autonomy of the man 
who in the eyes of the law, and indeed the family, is Sally’s father. Furthermore, it would 
leave the clinicians involved with important information about someone they had not 
imparted. Knowing whether or how to document this in the medical records, to ensure it is 
neither accidentally disclosed nor unnecessarily reinvestigated at some future time, needs 
careful consideration. 
 
Ethical arguments can be made both for and against disclosure in such cases.11 A commonly 
made argument against disclosure of misattributed parentage is that it is not directly relevant 
to clinical care. Whilst that is true in many cases, in this case the clinical relevance to 
reproductive autonomy is apparent. Another argument made against disclosure is that this 
information has the potential to undermine the family unit itself, resulting in harmful 
consequences and potentially leading to violence or abandonment that would not be in the 
best interests of either the child or the family as a whole. Although such harms are not easily 
predictable, and harms might also be caused where such information is withheld, this concern 
is a common response to this type of case. Another argument in favour of nondisclosure is 
that the family came to the clinic to find the cause of Sally’s condition and understand the 
risk of having a second affected child, but they did not (or at least not explicitly) come to find 
out about paternity (for which a test is available directly to the consumer).12 Their preferences 
about receiving this incidental and unsought for information, and likely responses to the 
result, cannot be determined without revealing the concern.  
 
Arguments in favour of disclosure also fall into a number of common positions. It is 
sometimes argued that not to inform the couple is unjustifiably paternalistic. The couple 
came to the doctor to seek information about their child’s condition, its causes and its 
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implication for their future reproductive health. The decision not to disclose means that they 
are not being given the information they seek. Nondisclosure draws upon assumptions about 
the consequences of such disclosure that cannot be foreseen and undermines the couple’s 
ability to make informed decisions about the future. A failure to disclose may also create 
confusion where previously there was none, particularly in cases where the couple are 
already aware of the situation or of its possibility (but have perhaps not realised the relevance 
to the diagnosis, so not declared it). In this context, withholding the information may simply 
reduce the chance of making a definitive genetic diagnosis and waste clinical time.  
 
It is clear from the above that many of the arguments both for and against disclosure (or 
nondisclosure) are grounded in concerns about its impact on children and their families. Data 
regarding the relative probability of these harms or benefits is largely absent, however, 
suggesting the need for caution in their utilisation in policy-making and practice without 
further research. In the absence of a convincing evidence-base, some have argued that the 
primarily duty is to avoid harm (a duty of non-maleficence).13 This argument seems more 
convincing in a research context and indeed, the consensus has generally been that the 
discovery of misattributed parentage ought not to be disclosed in a research setting where it is 
not relevant to the research question. Mandava et al. argue that “nondisclosure should be the 
default position for researchers”.14 In clinical practice, the issue has not previously arisen 
routinely because the use of parental testing to interpret a child’s result was rare until the 
advent of genomic medicine. Nevertheless, in the clinical setting, by contrast with that of 
research, recommendations over the last few decades have tended to emphasise the 
importance of explaining the potential of genetic testing to reveal family structure at the time 
of consent, and to be open and honest about results that have clinical significance.11 There is, 
however, a range of viewpoints in the literature,15–17 and despite an increased focus on 
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patient-centred medicine,18 the management of misattributed parentage remains challenging. 
Some, such as Palmore et al, 19 argue for a clause on the consent form “that any incidental 
information about parentage will not be revealed”. However, they do not consider cases 
where this policy would directly obfuscate information about risks for future children. 
 
It is our view that clinical significance should determine whether or not to disclose results in 
the clinic. Whilst there are situations in which nondisclosure is justifiable because it is clear 
that the finding of misattributed parentage has no clinical implications, it is unlikely to be 
justified in cases where inheritance patterns are crucial to the interpretation of a result, or for 
the delivery of clear and honest information about reproductive choice. Where there is a 
possibility of finding and disclosing misattributed parentage, either through clinical or 
research uses of genomics, this should be addressed during the consent or pre-test counselling 
process.20 The fact that genomic trio testing will determine biological relatedness – and 
therefore also detect misattributed parentage – should be made explicit through counselling, 
patient information sheets and/or consent forms, in any situation where it might affect a 
patient’s clinical management. Although disclosure policies may vary, couples can then make 
an informed decision as to whether they are content to go ahead with testing.  
 
Since misattributed parentage is relatively rare, a delicate balance must clearly be struck 
between managing the expectations of families and avoiding causing unnecessary distress to 
the vast majority of people to whom it will be an irrelevant possibility. Prevalence estimates 
vary from 1% to 30% (the Nuffield Council of Bioethics cites a “current best estimate of 1-
3%” from a range of studies,21 while a meta-analysis found a median of 4% across 17 
studies),22 although those with the  highest figures have demonstrable ascertainment bias, 
such as samples sent for paternity testing. Conversely, parents who know they are genetically 
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unrelated to their child may decide against sending a DNA sample to family sequencing 
studies if the unavoidable discovery of misattributed parentage is explained upfront. A 
robust, open and honest discussion could therefore substantially reduce both the prevalence 
and severity of any downstream harms.  
 
Summary 
 
The issue of misattributed parentage is not new, but our ability to discover it routinely is 
increasing in both quality and quantity as a result of high-throughput DNA sequencing 
technologies. This is further highlighted in situations, such as the case of baby Sally above, 
where the achievement of clarity about inheritance patterns (and hence about parentage) is 
core to the purpose of testing and determining a diagnosis. It is therefore crucial that genomic 
researchers and clinicians carefully consider how they will manage this unavoidable finding 
in the joint territory they increasingly inhabit. Both good research governance and good 
clinical practice demand consideration of the relative harms and benefits of disclosing 
information beyond the scope of the original enquiry. Clinical laboratories must carefully 
weigh the potential harms of testing genetic relatedness directly with the potential benefits of 
making a definitive diagnosis and facilitating reproductive counselling on a case-by-case 
basis. Ensuring that patients and families are aware of the possibility of revealing 
misattributed parentage, prior to consenting for testing, is also important to respect individual 
autonomy and minimising downstream harms. The fact that sensitive communication of 
information about misattributed parentage can be challenging is not a good enough reason to 
avoid such discussions.  
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A final note. The issue of misattributed parentage has wider implications for responsible data 
management. Since most genomic sequencing data are deposited into shared databases to 
facilitate research,23 perhaps the worst possible scenario would be a policy of nondisclosure 
of misattributed parentage to the clinical team and family, followed by unintentional 
disclosure and accidental discovery. Since it is an entirely anticipatable incidental finding, 
studies must therefore have a policy addressing the identification of misattributed parentage 
and an ethical framework for how the data will subsequently be handled.  
 
In conclusion, for hybrid research studies that routinely use trio sequencing and communicate 
results to clinicians, difficulties will necessarily arise if there is an explicit nondisclosure 
policy relating to misattributed parentage. Researchers must take exceptional care not to 
inadvertently reveal such information, and clinicians must decide whether to adhere strictly to 
the study’s policy or use their clinical judgement on a case-by-case basis. Where the 
information has clear clinical utility, and relates directly to the purpose of testing (such as 
reproductive counselling), we recommend this is discussed upfront in the consenting process 
and suggest that future policies should allow for more case-specific judgement around 
disclosure. 
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